drugset / Trial / NCT06664879
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
Phase 1/2
Active not recruiting
3 enrolled
M.D. Anderson Cancer Center
Australasian Leukaemia and Lymphoma Group · collab
NaSingle-groupOpen-labelTreatment
Summary
To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.
Timeline
- Start
- 2024-12-30
- Primary completion
- 2028-07-31
- Completion
- 2028-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Intravenous |
| Subject | Sabatolimab | Monoclonal antibody | — | Intravenous |